UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

The Lancet (British edition), 2010-12, Vol.376 (9757), p.1989-1999

2010

Volltextzugriff (PDF)

The feasibility and acceptability of a primary school-based programme targeting diet and physical activity: the PhunkyFoods Programme

Pilot and feasibility studies, 2019-12, Vol.5 (1), p.152-152, Article 152

2019

Volltextzugriff (PDF)

How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales

Quality of life research, 2023-05, Vol.32 (5), p.1247-1253

2023

Volltextzugriff (PDF)

The impact of COVID-19 on PRO development, collection and implementation: views of UK and Ireland professionals

Journal of patient-reported outcomes, 2023-11, Vol.7 (1), p.121-121, Article 121

2023

Volltextzugriff (PDF)

Sample size calculations for pilot randomized trials: a confidence interval approach

Journal of clinical epidemiology, 2013-02, Vol.66 (2), p.197-201

2013

Volltextzugriff (PDF)

P16.38: Healthcare Resource Utilization in Transplant Recipients With Cytomegalovirus Infection Refractory to Prior Treatment With/Without Resistance Receiving Maribavir Versus Investigatorassigned Therapy: Exploratory Analysis of the Phase 3 SOLSTICE Trial

Transplantation, 2022-09, Vol.106 (9S), p.S746-S747

2022

Volltextzugriff (PDF)

Painful leg ulceration: a prospective, longitudinal cohort study

Wound repair and regeneration, 2007-03, Vol.15 (2), p.186-191

2007

Volltextzugriff (PDF)

Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival

Clinical cancer research, 2008-03, Vol.14 (6), p.1775-1781

2008

Volltextzugriff (PDF)

Correction: How strong should my anchor be for estimating group and individual level meaningful change? A simulation study assessing anchor correlation strength and the impact of sample size, distribution of change scores and methodology on establishing a true meaningful change threshold

Quality of life research, 2023-05, Vol.32 (5), p.1265-1265

2023

Volltextzugriff (PDF)

Can patient involvement improve patient safety? A cluster randomised control trial of the Patient Reporting and Action for a Safe Environment (PRASE) intervention

BMJ quality & safety, 2017-08, Vol.26 (8), p.622-631

2017

Volltextzugriff (PDF)

Healthcare resource utilization of maribavir versus investigator‐assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial

Transplant infectious disease, 2023-06, Vol.25 (3), p.e14064-n/a

2023

Volltextzugriff (PDF)

Health State Utility Values in Paediatric Subjects with Partial Onset Seizures (POS) or Primary Generalized Tonic Clonic Seizures (PGTCS) receiving Adjunctive Perampanel (4217)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Can staff and patient perspectives on hospital safety predict harm-free care? An analysis of staff and patient survey data and routinely collected outcomes

BMJ quality & safety, 2015-06, Vol.24 (6), p.369-376

2015

Volltextzugriff (PDF)

Improving patient safety through the involvement of patients: development and evaluation of novel interventions to engage patients in preventing patient safety incidents and protecting them against unintended harm

Programme grants for applied research, 2016-10, Vol.4 (15), p.1-296

2016

Volltextzugriff (PDF)

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m.sup.2 vs. twice-weekly 27 mg/m.sup.2 carfilzomib (randomized A.R.R.O.W. study)

Leukemia, 2019-12, Vol.33 (12), p.2934

2019

Volltextzugriff (PDF)

A Mixed Methods Approach to Generate Meaningful Change Estimates for the EORTC QLQ-MY20

Blood, 2018-11, Vol.132 (Supplement 1), p.5912-5912

2018

Volltextzugriff (PDF)

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Blood, 2019-11, Vol.134 (Supplement_1), p.3480-3480

2019

Volltextzugriff (PDF)

P-131: Use of the European Organisation for research and treatment of cancer quality of life Multiple Myeloma questionnaire (EORTC QLQ-MY20): a review of the literature 25 years after development

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S106-S107

2021

Volltextzugriff (PDF)

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

Journal of clinical oncology, 2016-11, Vol.34 (32), p.3921-3930

2016

Volltextzugriff (PDF)

Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials

Value in health, 2023-10, Vol.26 (10), p.1543-1548

2023

Volltextzugriff (PDF)

Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials” [Lung Cancer 167C (2022) 65–72]

Lung cancer (Amsterdam, Netherlands), 2022-09, Vol.171, p.126-126

2022

Volltextzugriff (PDF)

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.2288-2288

2018

Volltextzugriff (PDF)

Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9057-9057

2021

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Aktive Filter

ThemaQuality Of Life

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

The feasibility and acceptability of a primary school-based programme targeting diet and physical activity: the PhunkyFoods Programme

How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

The impact of COVID-19 on PRO development, collection and implementation: views of UK and Ireland professionals

Sample size calculations for pilot randomized trials: a confidence interval approach

P1683: THE EORTC QLQ‐HL27: EORTC PROSPECTIVE INTERNATIONAL VALIDATION OF A DISEASE‐SPECIFIC QUESTIONNAIRE FOR ASSESSMENT OF HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA

P16.38: Healthcare Resource Utilization in Transplant Recipients With Cytomegalovirus Infection Refractory to Prior Treatment With/Without Resistance Receiving Maribavir Versus Investigatorassigned Therapy: Exploratory Analysis of the Phase 3 SOLSTICE Trial

Painful leg ulceration: a prospective, longitudinal cohort study

Prognostic Factors in Renal Cell Carcinoma: Association of Preoperative Sodium Concentration with Survival

Correction: How strong should my anchor be for estimating group and individual level meaningful change? A simulation study assessing anchor correlation strength and the impact of sample size, distribution of change scores and methodology on establishing a true meaningful change threshold

Can patient involvement improve patient safety? A cluster randomised control trial of the Patient Reporting and Action for a Safe Environment (PRASE) intervention

Healthcare resource utilization of maribavir versus investigator‐assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment: Exploratory analysis of the Phase 3 SOLSTICE trial

Health State Utility Values in Paediatric Subjects with Partial Onset Seizures (POS) or Primary Generalized Tonic Clonic Seizures (PGTCS) receiving Adjunctive Perampanel (4217)

Can staff and patient perspectives on hospital safety predict harm-free care? An analysis of staff and patient survey data and routinely collected outcomes

Improving patient safety through the involvement of patients: development and evaluation of novel interventions to engage patients in preventing patient safety incidents and protecting them against unintended harm

Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m.sup.2 vs. twice-weekly 27 mg/m.sup.2 carfilzomib (randomized A.R.R.O.W. study)

A Mixed Methods Approach to Generate Meaningful Change Estimates for the EORTC QLQ-MY20

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

P-131: Use of the European Organisation for research and treatment of cancer quality of life Multiple Myeloma questionnaire (EORTC QLQ-MY20): a review of the literature 25 years after development

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma

Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials

Corrigendum to “Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials” [Lung Cancer 167C (2022) 65–72]

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC)

Aktive Filter

Suchergebnisse filtern